Objectives/Hypothesis: Vocal fold fibroblasts (VFF) are responsible for extracellular matrix synthesis supporting lamina propria in normal and diseased conditions. When tissue is injured, VFF become activated and differentiate into myofibroblasts to facilitate wound healing response. We investigated if vocal fold myofibroblasts can be utilized as surrogate cells for scarred VFF.
INTRODUCTION
Vocal fold lamina propria is composed of extracellular matrix (ECM) rich in collagen; elastin; hyaluronic acid; fibromodulin; versican, among other proteins; blood vessels; and fibroblasts. 1, 2 Vocal fold fibroblasts (VFF) are responsible for ECM synthesis, playing a key role in support of the lamina propria in normal and diseased conditions. During tissue injury, VFF become activated and differentiate into myofibroblasts, initiating contractual properties and increasing catalysis of ECM in order to facilitate wound healing [3] [4] [5] [6] [7] and promote tissue repair. 8 Left unregulated, prolonged presence of myofibroblasts during wound healing can result in the development of fibroproliferative diseases and tumors 9 and play a role in aging. 10 One major limitation in the field of vocal fold biology is the lack of cell lines for normal and diseased states. There are no commercial VFF cells lines from patients who have vocal fold scarring or injury. Further in vitro vocal fold biology investigations and lamina propria biomaterial designs have generally been studied with normal VFF. Although this approach has yielded significant advances, it fails to capture several aspects of the in vivo diseased environment, which critically impacts the quality and rate of VFF matrix synthesis. For instance, fibroblasts associated with chronic vocal fold scar often display myofibroblastic or fibrotic phenotype, whereas the VFF employed in most in vitro biomaterial studies are normal. Development of a surrogate cell type would provide a more realistic in vitro environment for the study of vocal fold wound healing.
In 2010, Vyas et al. 5 developed a myofibroblast cell culture model to characterize and understand the molecular mechanism of VFF differentiation and function in injured vocal fold tissue. These authors treated VFF with transforming growth factor beta 1 (TGFb1) for 7 days; alpha smooth muscle actin (a-SMA) expression was demonstrated with TGFb1 treatment indicating that VFF were capable of differentiating into myofibroblasts. More recently, Jett e et al. 7 evaluated morphology, kinetic growth, contractile properties, and a-SMA protein and gene expression between normal and scarred VFF because they were able to obtain rare human vocal fold scar tissue. Not surprisingly, differences were measured between normal and scar VFF in terms of proliferation capacity, as well as a-SMA level and gene expression.
The objective of the present investigation was to confirm if the myofibroblast model developed by Vyas et al. 5 could be utilized as scarred VFF surrogate cells. We characterized and compared genotype and phenotype of normal VFF treated with TGFb1 (myofibroblasts) to human primary scarred VFF. If successful, a reproducible, characterized method for obtaining VFF that behave as scarred VFF would have far-reaching implications and impact on the field of biology of the vocal fold lamina propria because these would provide a valuable research tool.
MATERIALS AND METHODS
Fibroblasts from normal vocal folds were obtained from a 21-year-old male (N21), a 59-year-old female (N59), and a scar vocal fold from 56-year-old female (S56), as previously reported.
11,12
Cell Culture and Treatment With TGFb1
When cells reached 70% to 80% confluence, they are trypsinized and counted. Cells were subcultured into new plates and incubated at 378C with 5% CO2. Passages 6 to 9 were utilized for this experiment, indicating the number of growth passages undertaken by these cells. Cells were plated on 10-cm dishes (2 3 10 5 cells/dish) for western blot, RNA, and collagen contraction assays. For growth and proliferation assays, cells were plated in 24-well plates with 1.5 3 10 4 cells/well in order to facilitate the cell counting and photos capturing. For immunocytochemistry, 1,000 cells were seated on coverslips placed inside the wells of a 12-well dish containing 5% fetal bovine serum (FBS; Sigma, St. Louis, MO) for 24 hours, followed by 24 hours of serum starvation. Cells received either 5 days of treatment of media 2.5% FBS 1 10 ng/ml TGFb1 (N211 and N591) or media 2.5% FBS with no added TGFb1 (N212, N592, S56).
To avoid contamination risk between cells treated with and without TGFb1, we used separated supplies for the experiment.
Morphology and Proliferation
Fibroblast categorization and identification has previously been reported. 11 Morphological analysis photos were taken for 6 days using EVOS Color Imaging microscope (AMG, Bothell, WA). For growth and proliferation, after 5 days of with/without TGFb1treatment, VFF were trypsinized and counted by hemocytometer. Cells from four random wells were counted each day for 6 days. Experiments were performed by quadruplicate.
Gene Expression Analysis
To analyze changes to ECM and growth factor genes after differentiation into myofibroblasts, we measured mRNA expression of collagen 1 and 3, fibronectin, a-SMA, matrix metallopeptidase (MMP1), metallopeptidase inhibitor (TIMP3), connective tissue growth factor (CTGF), hepatocyte growth factor (HGF), TGFb1, and vascular endothelial growth factor. After TGFb1 treatment, total RNA was extracted from VFF using RNeasy Mini Kit (Qiagen, Valencia, CA). First, strand cDNA was synthesized from 2 lg of total RNA using an Omniscript Reverse Transcription Kit (Qiagen, Valencia, CA). SYBR Select Master Mix (Life Technologies, Carlsbad, CA) was used with Applied Biosystem 7500 Fast System (Life Technologies, Carlsbad, CA) using a relative quantification standard curve. Amplification of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. Eight-point standard curves were constructed with dilutions of polymerase chain reaction (PCR) template with known mass concentrations. Amplified product was isolated from 1% agarose gel following electrophoresis using QAIquick gel extraction kit (Qiagen, Valencia, CA). Expression level of the target gene was normalized to the housekeeping gene. Experiments were done in triplicate.
Primer sequences, gene bank access numbers, and expected PCR product sizes are listed in Table I for CTGF and GAPDH. Other primers have been previously described. [12] [13] [14] [15] Each primer pair was confirmed by melting curves and PCR reactions, which showed a single peak and appropriate sized DNA band for each gene product. Collagen 1 
Immunocytochemistry
After VFF differentiation, coverslips were washed with phosphate buffered saline (PBS), fixed in 4% paraformaldehyde for 10 minutes at room temperature and washed three times with buffer composed by 1% Triton X-100 (Sigma, St. Louis, MO) diluted in PBS. Coverslips were incubated in 0.5% TritonX-100 buffer (Sigma, St. Louis, MO). After 10 minutes, blocking buffer was added (2% bovine serum albumin (BSA) and 10% goat serum) for 30 minutes, followed by primary antibody anti-mouse a-SMA (Sigma, St. Louis, MO) at 1:250 dilution with 2% BSA in PBS. After 90 minutes, cells were thoroughly washed in 1% Triton X-100 (Sigma, St. Louis, MO) diluted in PBS. Secondary a-mouse (goat A488, Invitrogen, Carlsbad, CA) antibody diluted to 1:200 was applied. After 1 hour, coverslips were washed and slides were prepared using Vectashield (Vector Laboratories, Burlingame, CA) with 4 0 ,6-diamidino-2-phenylindole (DAPI). Images were captured by Nikon Eclipse E600 Fluorescence inverted microscope (Nikon, Tokyo, Japan).
Western Blot
Vocal fold fibroblasts grown for 5 days in 10-cm dishes were washed with PBS, and proteins were extracted using M-PER Protein kit (Pierce, Rockford, IL). Total protein was quantified by bicinchoninic acid assay (Pierce, Rockford, IL). For each protein sample, 1.5 lg of total protein was characterized by electrophoresis on NuPage 10% Bis-Tris gels using Life technologies XCell SureLock mini-cell system (Invitrogen, Carlsbad, CA). Membranes were blocked overnight and probed with antibodies to SMA (mouse monoclonal a-SMA, 1:1,000; Sigma, St. Louis, MO) and GAPDH (1:20,000; Sigma, St. Louis, MO) using Life Technologies Western Breeze Chemiluminescent Western Blot Immunodetection kit.
Collagen Contraction Assay
After 5 days of TGFb1 treatment, treated and untreated cells were plated at densities of 600,000 cells/well and seeded into wells, each containing 0.5 ml of collagen gel lattice (Biolabs, San Diego, CA). After polymerization, 1 ml of culture medium was added. After 2 days of culture, stressed matrices were released from the surrounding brim of wells using a sterile pipette tip. Photos of free-floating collagen gel lattices were taken immediately after the gel release (0 hours-control), 24 hours and 60 hours. Areas of collagen gel size were analyzed with ImageJ (National Institutes of Health, Bethesda, MD) and normalized to areas of the well. Degree of contraction was evaluated by determining the area of the gel matrix. Assays were run in triplicate for each cell group (N211, N212, N591, N592, and S56), and a cell-free collagen matrix was used as comparison control.
Statistical Analysis
Analysis of variance (ANOVA) was used to analyze proliferation of cells across days with Fisher tests, with statistical significance assigned at P < 0.05. Degree of collagen contraction was compared across each time (0, 24, and 60 hours) and group (N211, N212, N591, N592, and S56 VFF) using ANOVA and Fisher tests with statistical significance assigned at P < 0.05. For gene expression, comparisons were made between the normalized gene expression values across the five different experimental conditions for all genes by Tukey-Kramer test. P < 0.05 was considered statistically significant.
RESULTS

Morphology, Growth, and Proliferation
Vocal fold fibroblasts (N211, N212, N591, N592, and S56) presented a spindle-shaped pattern (Fig. 1) . On day 1, scar VFF were larger. At day 6, N211 and N591 were bigger than N212 and N592, and more similar to S56. Observing VFF growth curves (Fig. 2) , we found ascendent VFF proliferation. N211 and N212 showed the greatest growth rate compared to N591, N592, and S56. Differences in growth rate were measured on day 5, with N211 having significantly greater growth rate compared to N592 (P < 0.0001) and N591 (P 5 0.0059). N212 showed significantly higher growth rates compared to N592 (P < 0.0001). S56 had significantly greater growth rate compared to N592 (P 5 0.0016). On day 6, N211 and N212 maintained similar growth rates, distancing themselves even more from S56, N591, and N592 (P < 0.0001).
Gene Expression
Gene expression for N211, N212, N591, N592, and S56 VFF are shown in Figure 3 . In summary, N211 and N591 VFF demonstrated the highest gene expression for fibronectin, TIMP3, a-SMA, and CTGF compared to those VFF not treated with TGFb1 and S56 VFF.
Fibronectin was significantly higher in N591 compared to S56, N592, and N212 (P < 0.0001). Fibronectin was also significantly higher in N211 compared to N212, N592, and S56 (P < 0.0001). No differences were measured in expression of collagen 3 between groups. Collagen 1 was significantly higher in N591 compared to N212 (P 5 0.0107) and N592 compared to N212 (P 5 0.0425).
a-SMA had significantly higher expression for N211 compared to S56 (P 5 0.0103); the N211 condition had significantly higher expression compared to the N212 (P 5 0.0104) and N592 (P 5 0.0116). No differences were measured for TGFb1 expression between VFF groups.
TIMP3 was significantly higher in N591 compared to N212 (P < 0.0001), N592 (P 5 0.0009), and S56 (P 5 0008). MMP1 had significantly higher expression in N212compared to N592 (P 5 0.0060) and N591 compared to N592 (P 5 0.0170).
CTGF was significantly higher expressed in N591 compared to N212, N592, and S56 VFF (P < 0.0001). HGF expression was significantly greater in N592 compared to N211 (P < 0.0001) and N591 (P < 0.0001). N592 also had significantly higher expression of HGF compared to S56 (P 5 0.0272) and N212 (P 5 0.0475). No significant differences were seen in VEGF expression across groups.
Immunocytochemistry and Western Blot
With immunocytochemistry, a-SMA expression was observed in all cell types. Differences were observed in N211 and N591 with higher a-SMA expression (Fig. 4) . Higher N211 and N591 a-SMA expression was also confirmed in western blot analysis (Fig. 4) when compared to N212, N592, and S56 VFF versus loading control.
Collagen Contraction
After edges were liberated from arrays wells, we observed collagen lattice contraction at 0 hours, 24 hours, and 60 hours (Fig. 5) . No differences in collagen contraction were observed at 0 hours between any of the groups. At 24 hours, VFF treated with TGFb1 had the highest collagen contraction compared to N212, N592, S56, and no cell. N591 showed significantly higher collagen contraction matrix compared to no cell (P 5 0.0002) and S56 (P 5 0.0020). N211 had significantly higher collagen contraction compared to no cell (P 5 0.0091) and S56 (P 5 0.0490). Higher collagen contraction was observed for the N592 group compared to no cell group (P 5 0.0462). At the 60-hour time point, N592 had significantly higher contraction of collagen lattice compared to no cell group (P < 0.0001). N212, N211, and N591 had higher collagen contraction matrices compared to no cell group (P < 0.0001). S56 showed significantly lower collagen contraction matrix compared to N211 (P 5 0.0290), N212 (P 5 0.0003), N591 (P 5 0.0408), and N592 (P < 0.0001). S56 showed difference when compared with no cell group (P 5 0.0497).
DISCUSSION
Vocal fold fibroblasts provide structural support to the lamina propria by producing growth factors and matrix fibers. 1, 16, 17 In the presence of vocal fold scar, fibroblasts exhibit an unbalanced production of ECM components, leading to fibrosis. 18 The ability of myofibroblasts to generate contractile forces is due to accumulation of cytoplasm and cellular fibronectin, resulting from ECM reorganization. 19 Myofibroblasts that express a-SMA are considered to be activated contractile fibroblasts and primarily responsible for excessive ECM contraction deposition with scar. 7 In this investigation, we compared vocal fold myofibroblasts produced via treatment of normal VFF with TGFb1 to VFF taken from vocal fold scar tissue. Vocal fold fibroblasts treated with or without TGFb1 showed a similar elongated (fusiform)-shape pattern, confirming previously published reports. 7, 12, 14, 20 However, differences in proliferation indicate that age may be a more important factor for growth than treatment groups. Measured differences correlate with Jett e et al., 7 who demonstrated lower growth for a 56-year-old scar VFF donor compared to normal VFF. Decrease in fibroblast proliferation may be an integral part in the progression of the aging and fibrosis processes. 21 Human aged larynges have less fibroblasts as compared with young adults, 22 suggesting a decrease in the number of fibroblasts with age. An increase in the proliferation capacity demonstrated by the N211 and N212 VFF in the present study further demonstrates that age may influence cell growth and proliferation. Similar results were reported by Chen and Thibeault, 12 whereby higher growth and proliferation rates were measured from young VFF cells versus old.
Specific to fibroblast-myofibroblast differentiation, changes in gene expression may be a designate of an activated state 19 that corresponds to chronic vocal fold scarring. Results demonstrate that VFF treated with TGFb1 had the highest gene expression levels compared to no treatment and scar groups. Fibronectin was highly expressed in VFF treated with TFGb1, denoting that TGFb1 increases the ability of fibroblasts to incorporate fibronectin into ECM. 23 Fibronectin and a-SMA are directly linked to ECM structure and functionality. Fibronectin is a glycoprotein produced by fibroblasts in the lamina propria and basal membrane that participates in adhesion, differentiation, and cell maintenance. It is also observed in higher expression in injured vocal folds by constant trauma such as in nodules. 24 In scar vocal folds, fibronectin accelerates wound healing providing collagen deposition and cell migration. 25 a-SMA is a well-accepted marker of myofibroblast differentiation 26 that is responsible for contraction during wound healing by its stress fibers. 27, 28 In rodents, Kumai et al. 29 evaluated expression of a-SMA in normal and scar vocal folds observing greater a-SMA expression in scar vocal folds. We found higher a-SMA gene expression in N21 and N59 VFF treated with TGFb1. Scar VFF expression was similar to N212 and N592.
CTGF is a gene that participates in wound healing, stimulating cell proliferation and adhesion, angiogenesis, and ECM production. During the repair process, TGFb1 and CGTF work in partnership to stimulate matrix deposition. 30 In this study, CTGF was expressed in all cells groups, with the highest expression in N21 and N59 treated with TGFb1. It appears that CTGF expression was stimulated with TGFb1 treatment and expressed concomitantly with a-SMA myofibroblast differentiation and collagen matrix contraction by TGFb1 action, as previously reported for corneal 31 and kidney fibroblasts. 32 Present immunocytochemistry and confirmation by western blot indicated that a-SMA was expressed in all cells, although the treatment of N211 and N591 had slightly higher staining in immunocytochemistry and strong signals in western blot. Myofibroblast phenotype expression in normal VFF, without TGFb1, leads us to infer three reasons to explain this finding: 1-a-SMA expression may be present during cell cycle progression in fibroblast culture, 7, 33, 34 particularly in monolayer cultures. 5 2-Fibroblasts are subjected to various types of mechanical forces during phonation, 35 and vibration may stimulate a-SMA expression in response to tension. 36 Myofibroblasts are a subset of specialized cells with fibroblast and smooth muscle cells characteristics; thus, the main marker for these cells is a-SMA expression in cytoplasmic stress fibers. These cells maintain tension along their bodies by sustained myosin ATPase activity, ensuring tension and cell contraction. 37 VFF may have myofilaments as stress fibers due to its tensional homeostasis. 3-TGFb1 may up-regulate a-SMA expression 38 in VFF as in stimulated gingival and pulpal fibroblasts. 39 It is well established that TGFb1 is involved in myofibroblast differentiation to initiate the contractile apparatus 40 that is necessary to generate forces for collagen-rich scar formation. For this reason, we performed a collagen contraction assay to investigate the degree of collagen contraction matrices. Analysis showed reduced contraction in S56 VFF; however, Jett e et al. 7 found no contraction differences between normal and scar VFF at 24 and 48 hours with a similar collagen contraction assay. In a dermal hypertrophic scar study, Zhang et al. 41 utilized decorin into fibroblast-populated collagen lattice and reported that, when TGFb1 was added, hypertrophic scar fibroblasts showed greater contraction of collagen gels than normal fibroblasts. Differences in collagen contraction lattices were found between scar and normal dermal VFF 42 ; however, these authors demonstrated that scar VFF had lower collagen contraction and higher a-SMA expression.
CONCLUSION
VFF treated with TGFb1 (myofibroblasts) appear to have similar phenotypic characteristics but different genotypic behavior compared to scar VFF. VFF treated with or without TGFb1 showed similar elongated (fusiform) shape feature. N21 VFF with or without TGFb1 demonstrated significantly greater proliferation compared to N591, N592, and S56 VFF. N21 and N59 VFF treated with TGFb1 had the highest gene expression levels to fibronectin, a-SMA, CTGF, and TIMP3 when compared to no treatment and scar groups. S56 VFF showed lower collagen contraction compared to N21 and N59 VFF treated with TGFb1 at 24 hours; but at 60 hours, S56 VFF had lower collagen contraction compared to all cell groups.
Further investigation is warranted into the differences in age of donor and different stages of wound healing to fully understand the role of the myofibroblasts in scar vocal folds. According the relationship between VFF treated with TGFb1 and scarred VFF may not be as forthright as first expected.
